Sensei Biotherapeutics (NASDAQ:FTH) CFO Purchases 831 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 831 shares of the stock in a transaction dated Monday, June 29th. The stock was bought at an average price of $23.34 per share, with a total value of $19,395.54. Following the purchase, the chief financial officer owned 33,885 shares of the company’s stock, valued at approximately $790,875.90. This represents a 2.51% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sensei Biotherapeutics Price Performance

Shares of Sensei Biotherapeutics stock traded down $1.34 during trading hours on Wednesday, hitting $23.66. 114,325 shares of the company’s stock traded hands, compared to its average volume of 89,623. Sensei Biotherapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $36.76. The company has a market capitalization of $31.70 million, a PE ratio of -0.17 and a beta of -0.26.

Analyst Ratings Changes

FTH has been the topic of a number of research analyst reports. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective for the company. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, HC Wainwright started coverage on shares of Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sensei Biotherapeutics has a consensus rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.